The goal of Tumor Immunology Training Program (TITP) is to prepare predoctoral students for a career in the application of immunological approaches to the diagnosis, prevention and treatment of cancer. Future scientific leaders in tumor immunology must not only be well-trained immunologists, they must also be able to appreciate the challenges in applying basic immunology techniques to clinically relevant questions. Toward that end the TITP stresses the importance of the development of translational research programs and encourages the interaction of pre-clinical and clinical research programs vital to the training of successful graduates. The TITP provides trainees with an advanced broad-based education with opportunities for focused training in all aspects of tumor immunology including translational aspects. The uniqueness of this training program is further augmented by the integration of an academic program comprised of diverse faculty within the setting of a world-renowned, NCI-designated, Comprehensive Cancer Center. Trainees are exposed to a broad perspective of cancer-related issues including cancer incidence and survival, the spectrum of scientific approaches to cancer and the realities of patient care. Furthermore, the training experience TITP students receive is augmented by the close proximity of Roswell Park Cancer Institute to the State University of New York at Buffalo. The primary mission of the proposed training grant is to support students during their second year of graduate study. During this time the students complete their didactic course requirements and laboratory rotations, select a Thesis Advisor and Thesis Advisory committee, prepare a research proposal and take a preliminary examination for advancement to candidacy. The requested training grant funds cover stipends and tuition costs for 4 predoctoral students per year. The Thesis Advisor assumes responsibility for financial support of the student beginning in the third year of study and continuing through completion of the degree. Students who successfully complete this training program will be well versed in all aspects of tumor immunology and will have the background necessary to establish clinically relevant research laboratories designed toward the development of novel therapies that are able to counteract tumor escape mechanisms.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA085183-08
Application #
7682053
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
2000-04-01
Project End
2012-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
8
Fiscal Year
2009
Total Cost
$108,208
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Sass, Stephanie N; Ramsey, Kimberley D; Egan, Shawn M et al. (2018) Tumor-associated myeloid cells promote tumorigenesis of non-tumorigenic human and murine prostatic epithelial cell lines. Cancer Immunol Immunother 67:873-883
Qiao, Guanxi; Chen, Minhui; Bucsek, Mark J et al. (2018) Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. Front Immunol 9:164
Burkard-Mandel, Lauren; O'Neill, Rachel; Colligan, Sean et al. (2018) Tumor-derived thymic stromal lymphopoietin enhances lung metastasis through an alveolar macrophage-dependent mechanism. Oncoimmunology 7:e1419115
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Bucsek, Mark J; Giridharan, Thejaswini; MacDonald, Cameron R et al. (2018) An overview of the role of sympathetic regulation of immune responses in infectious disease and autoimmunity. Int J Hyperthermia 34:135-143
Bianchi-Smiraglia, Anna; Bagati, Archis; Fink, Emily E et al. (2018) Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma. J Clin Invest 128:4682-4696
Bucsek, Mark J; Qiao, Guanxi; MacDonald, Cameron R et al. (2017) ?-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy. Cancer Res 77:5639-5651
Egan, Shawn M; Karasik, Ellen; Ellis, Leigh et al. (2017) miR-30e* is overexpressed in prostate cancer and promotes NF-?B-mediated proliferation and tumor growth. Oncotarget 8:67626-67638
Szender, J Brian; Emmons, Tiffany; Belliotti, Sarah et al. (2017) Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecol Oncol 146:491-497
Leigh, Nicholas D; O'Neill, Rachel E; Du, Wei et al. (2017) Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function. J Immunol 199:336-347

Showing the most recent 10 out of 60 publications